Edgewise Therapeutics, Inc. (EWTX) stock
EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$42.04−1.64 (-3.75%)
Close on Nov 17, 2026Market cap $4.57BP/E –Yield –
Edgewise Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Edgewise Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $171.27M, up 23.3% year over year. For fiscal 2025 it was $151.39M, up 19.2% from the year before. The highest annual figure on record is $151.39M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.39M | +19.2% |
| FY2024 | Dec 31, 2024 | $126.97M | +39.7% |
| FY2023 | Dec 31, 2023 | $90.91M | +68.2% |
| FY2022 | Dec 31, 2022 | $54.03M | +67.9% |
| FY2021 | Dec 31, 2021 | $32.19M | +114.8% |
| FY2020 | Dec 31, 2020 | $14.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $47.55M | +41.7% |
| Q1 FY2026 | Mar 31, 2026 | $42.65M | +16.0% |
| Q4 FY2025 | Dec 31, 2025 | $43.59M | +19.9% |
| Q3 FY2025 | Sep 30, 2025 | $37.48M | +16.3% |
| Q2 FY2025 | Jun 30, 2025 | $33.56M | +9.4% |
| Q1 FY2025 | Mar 31, 2025 | $36.76M | +32.7% |
| Q4 FY2024 | Dec 31, 2024 | $36.37M | +31.4% |
| Q3 FY2024 | Sep 30, 2024 | $32.22M | +35.5% |
| Q2 FY2024 | Jun 30, 2024 | $30.68M | +56.9% |
| Q1 FY2024 | Mar 31, 2024 | $27.69M | +39.3% |
| Q4 FY2023 | Dec 31, 2023 | $27.68M | +66.7% |
| Q3 FY2023 | Sep 30, 2023 | $23.79M | +71.2% |
| Q2 FY2023 | Jun 30, 2023 | $19.56M | +57.7% |
| Q1 FY2023 | Mar 31, 2023 | $19.88M | +78.7% |
| Q4 FY2022 | Dec 31, 2022 | $16.61M | +82.8% |
| Q3 FY2022 | Sep 30, 2022 | $13.89M | +40.6% |
| Q2 FY2022 | Jun 30, 2022 | $12.40M | +57.8% |
| Q1 FY2022 | Mar 31, 2022 | $11.12M | +107.5% |
| Q4 FY2021 | Dec 31, 2021 | $9.09M | +76.8% |
| Q3 FY2021 | Sep 30, 2021 | $9.88M | +205.1% |
| Q2 FY2021 | Jun 30, 2021 | $7.86M | +116.0% |
| Q1 FY2021 | Mar 31, 2021 | $5.36M | +80.7% |
| Q4 FY2020 | Dec 31, 2020 | $5.14M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.24M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.64M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.97M | – |
See a number that looks wrong?